CN105008524A - 用于治疗脑癌的组合物和方法 - Google Patents

用于治疗脑癌的组合物和方法 Download PDF

Info

Publication number
CN105008524A
CN105008524A CN201280077698.6A CN201280077698A CN105008524A CN 105008524 A CN105008524 A CN 105008524A CN 201280077698 A CN201280077698 A CN 201280077698A CN 105008524 A CN105008524 A CN 105008524A
Authority
CN
China
Prior art keywords
sequence
seq
virion
separation
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280077698.6A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·斯托多
约翰·卡梅伦·贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Limited Partnership
Original Assignee
Ottawa Health Research Institute
Childrens Hospital of Eastern Ontario CHEO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ottawa Health Research Institute, Childrens Hospital of Eastern Ontario CHEO filed Critical Ottawa Health Research Institute
Publication of CN105008524A publication Critical patent/CN105008524A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20233—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation
    • C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CN201280077698.6A 2012-12-12 2012-12-12 用于治疗脑癌的组合物和方法 Pending CN105008524A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2012/050893 WO2014089668A1 (en) 2012-12-12 2012-12-12 Compositions and methods for the treatment of brain cancers

Publications (1)

Publication Number Publication Date
CN105008524A true CN105008524A (zh) 2015-10-28

Family

ID=50933623

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280077698.6A Pending CN105008524A (zh) 2012-12-12 2012-12-12 用于治疗脑癌的组合物和方法

Country Status (11)

Country Link
US (1) US20150307559A1 (enExample)
EP (1) EP2931880B1 (enExample)
JP (1) JP6162818B2 (enExample)
CN (1) CN105008524A (enExample)
AU (1) AU2012396787B9 (enExample)
BR (1) BR112015013669A2 (enExample)
CA (1) CA2894618A1 (enExample)
IL (1) IL239374B (enExample)
MX (1) MX366493B (enExample)
RU (1) RU2705244C2 (enExample)
WO (1) WO2014089668A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110636853A (zh) * 2017-05-19 2019-12-31 佐治亚州立大学研究基金会公司 重组溶瘤病毒
CN113993883A (zh) * 2019-08-29 2022-01-28 渥太华Hdl药物研发公司 一种多肽及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045729B2 (en) 2009-12-10 2015-06-02 Ottawa Hospital Research Institute Oncolytic rhabdovirus
WO2012167382A1 (en) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
WO2014127478A1 (en) 2013-02-21 2014-08-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
PL3684786T3 (pl) * 2017-09-22 2024-12-16 Centre National De La Recherche Scientifique (Cnrs) Zmutowana glikoproteina wirusa pęcherzykowego zapalenia jamy ustnej
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
US12440564B2 (en) 2023-09-25 2025-10-14 Kelonia Therapeutics, Inc. Compositions for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2739963A1 (en) * 2008-10-08 2010-04-15 Tsanan Heimann Lcmv-gp-vsv pseudotyped vectors and tumor infiltrating virus-producing cells for the therapy of tumors
CN102026645A (zh) * 2006-09-15 2011-04-20 渥太华健康研究所 溶瘤弹状病毒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9307501A (en) * 2000-09-22 2002-04-02 Virxsys Improved conditionally replicating vectors, methods for their production and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102026645A (zh) * 2006-09-15 2011-04-20 渥太华健康研究所 溶瘤弹状病毒
CA2739963A1 (en) * 2008-10-08 2010-04-15 Tsanan Heimann Lcmv-gp-vsv pseudotyped vectors and tumor infiltrating virus-producing cells for the therapy of tumors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A MUIK 等: "Pseudotyping Vesicular Stomatitis Virus with Lymphocytic Choriomeningitis Virus Glycoproteins Enhances Infectivity for Glioma Cells and Minimizes Neurotropism", 《JOURNAL OF VIROLOGY》 *
BEYER, W. R. 等: "glycoprotein C [Lymphocytic choriomeningitis mammarenavirus]", 《GENBANK DATABASE》 *
BRUN J 等: "Identification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus", 《MOLECULAR THERAPY》 *
DJ WATSON 等: "Targeted Transduction Patterns in the Mouse Brain by Lentivirus Vectors Pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV Envelope Proteins", 《MOLECULAR THERAPY》 *
G WOLLMANN 等: "Oncolytic Virus Therapy of Glioblastoma Multiforme-Concepts and Candidates", 《CANCER JOURNAL》 *
J.ZHANG 等: "Oncolytic therapeutic potency of Farmington and modified maraba virus in immunocompetent intracranial glioma models and in mice bearing human brain tumor initiating cells models", 《NEURO-ONCOLOGY》 *
WR BEYER 等: "Oncoretrovirus and Lentivirus Vectors Pseudotyped with Lymphocytic Choriomeningitis Virus Glycoprotein: Generation, Concentration, and Broad Host Range", 《JOURNAL OF VIROLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110636853A (zh) * 2017-05-19 2019-12-31 佐治亚州立大学研究基金会公司 重组溶瘤病毒
CN113993883A (zh) * 2019-08-29 2022-01-28 渥太华Hdl药物研发公司 一种多肽及其应用

Also Published As

Publication number Publication date
EP2931880A4 (en) 2016-05-18
AU2012396787A1 (en) 2015-07-02
RU2015128078A (ru) 2019-03-27
MX2015007093A (es) 2016-01-12
MX366493B (es) 2019-07-10
IL239374A0 (en) 2015-07-30
IL239374B (en) 2021-03-25
RU2705244C2 (ru) 2019-11-06
JP6162818B2 (ja) 2017-07-12
JP2016501528A (ja) 2016-01-21
WO2014089668A1 (en) 2014-06-19
EP2931880B1 (en) 2019-03-20
AU2012396787B2 (en) 2019-09-19
AU2012396787B9 (en) 2019-10-03
EP2931880A1 (en) 2015-10-21
US20150307559A1 (en) 2015-10-29
CA2894618A1 (en) 2014-06-19
RU2015128078A3 (enExample) 2019-03-27
BR112015013669A2 (pt) 2017-11-14

Similar Documents

Publication Publication Date Title
CN105008524A (zh) 用于治疗脑癌的组合物和方法
JP2022091989A (ja) ウイルスベクター産生系
JP7239948B2 (ja) サイレント変異を有する組換えｒｓｖ、ワクチン、およびそれに関連する方法
KR100801180B1 (ko) 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
AU2022235209A1 (en) Minimal nephrin promoter
US20210346493A1 (en) SARS-COV-2 Antigen Polypeptide, Recombinant Adeno-Associated Virus Expressing the Polypeptide, and Vaccine Containing the Virus
US20120020995A1 (en) Parapoxvirus vectors
US20230293668A1 (en) Compositions and methods for glioblastoma treatment
WO2015154197A1 (en) Compositions and methods for glioblastoma treatment
CN114213505A (zh) 一种适用于特异感染u87-mg细胞的腺相关病毒突变体
CN117587014B (zh) 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用
EP2558113B1 (en) Serca2 therapeutic compositions and methods of use
WO2020012037A1 (en) Method for rescuing and producing a virus in avian cells
CN112111467A (zh) 一种基因vii型新城疫标记疫苗株及其制备方法与应用
CN120737216A (zh) 一种融合蛋白及其表达细胞株与应用
CN118406684A (zh) 一种shRNA腺相关病毒载体及其构建方法和应用
Seegers Experimental Evolution of Oncolytic Vesicular Stomatitis Viruses in Cancer Cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20170922

Address after: Ontario

Applicant after: Limited Partnership

Address before: Ontario

Applicant before: CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.

Applicant before: Ottawa Hospital Res Inst

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151028